MedTrace Logo

Comparison of Antiplatelet Effect of Ticagrelor vs Tirofiban in Patients With Non-ST Elevation Acute Coronary Syndrome

NCT01660373 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2012-12-18

No results posted yet for this study

Summary

This is a single-center, open-label prospective randomized pharmacodynamic investigation of two anti platelet regimens in patients who are planned to undergo PCI for non-ST segment elevation acute coronary syndrome(NSTE-ACS) for 24 hours

1. Ticagrelor : loading dose(180mg) followed by maintenance dose(90mg bid)
2. Tirofiban : 0.4ug/kg/min for 30min followed by 0.1ug/kg/min

* both agents will be given on top of aspirin

Conditions

  • Non-ST Segment Elevation Acute Coronary Syndrome

Interventions

DRUG

Tirofiban

0.4ug/kg/min for 30min followed by 0.1ug/kg/min

DRUG

Ticagrelor

loading dose(180mg) followed by maintenance dose(90mg bid)

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Pusan National University Yangsan Hospital

    lead OTHER

Principal Investigators

  • June Hong Kim, MD,PhD · Pusan National University Yangsan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01660373 on ClinicalTrials.gov